Literature DB >> 20442302

mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities.

Hongfang Liu1, Petula D'Andrade, Stephanie Fulmer-Smentek, Philip Lorenzi, Kurt W Kohn, John N Weinstein, Yves Pommier, William C Reinhold.   

Abstract

As part of the Spotlight on Molecular Profiling series, we present here new profiling studies of mRNA and microRNA expression for the 60 cell lines of the National Cancer Institute (NCI) Developmental Therapeutics program (DTP) drug screen (NCI-60) using the 41,000-probe Agilent Whole Human Genome Oligo Microarray and the 15,000-feature Agilent Human microRNA Microarray V2. The expression levels of approximately 21,000 genes and 723 human microRNAs were measured. These profiling studies include quadruplicate technical replicates for six and eight cell lines for mRNA and microRNA, respectively, and duplicates for the remaining cell lines. The resulting data sets are freely available and searchable online in our CellMiner database. The result indicates high reproducibility for both platforms and an essential biological similarity across the various cell types. The mRNA and microRNA expression levels were integrated with our previously published 1,429-compound database of anticancer activity obtained from the NCI DTP drug screen. Large blocks of both mRNAs and microRNAs were identified with predominately unidirectional correlations to approximately 1,300 drugs, including 121 drugs with known mechanisms of action. The data sets presented here will facilitate the identification of groups of mRNAs, microRNAs, and drugs that potentially affect and interact with one another.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20442302      PMCID: PMC2879615          DOI: 10.1158/1535-7163.MCT-09-0965

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  38 in total

Review 1.  Identification and characterization of small RNAs involved in RNA silencing.

Authors:  Alexei Aravin; Thomas Tuschl
Journal:  FEBS Lett       Date:  2005-08-18       Impact factor: 4.124

2.  Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study.

Authors:  Uma T Shankavaram; William C Reinhold; Satoshi Nishizuka; Sylvia Major; Daisaku Morita; Krishna K Chary; Mark A Reimers; Uwe Scherf; Ari Kahn; Douglas Dolginow; Jeffrey Cossman; Eric P Kaldjian; Dominic A Scudiero; Emanuel Petricoin; Lance Liotta; Jae K Lee; John N Weinstein
Journal:  Mol Cancer Ther       Date:  2007-03-05       Impact factor: 6.261

3.  Impact of normalization on miRNA microarray expression profiling.

Authors:  Sylvain Pradervand; Johann Weber; Jérôme Thomas; Manuel Bueno; Pratyaksha Wirapati; Karine Lefort; G Paolo Dotto; Keith Harshman
Journal:  RNA       Date:  2009-01-28       Impact factor: 4.942

Review 4.  The NCI60 human tumour cell line anticancer drug screen.

Authors:  Robert H Shoemaker
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

5.  An information-intensive approach to the molecular pharmacology of cancer.

Authors:  J N Weinstein; T G Myers; P M O'Connor; S H Friend; A J Fornace; K W Kohn; T Fojo; S E Bates; L V Rubinstein; N L Anderson; J K Buolamwini; W W van Osdol; A P Monks; D A Scudiero; E A Sausville; D W Zaharevitz; B Bunow; V N Viswanadhan; G S Johnson; R E Wittes; K D Paull
Journal:  Science       Date:  1997-01-17       Impact factor: 47.728

6.  let-7 microRNA functions as a potential growth suppressor in human colon cancer cells.

Authors:  Yukihiro Akao; Yoshihito Nakagawa; Tomoki Naoe
Journal:  Biol Pharm Bull       Date:  2006-05       Impact factor: 2.233

Review 7.  MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management.

Authors:  Aoife J Lowery; Nicola Miller; Roisin E McNeill; Michael J Kerin
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

8.  Neural computing in cancer drug development: predicting mechanism of action.

Authors:  J N Weinstein; K W Kohn; M R Grever; V N Viswanadhan; L V Rubinstein; A P Monks; D A Scudiero; L Welch; A D Koutsoukos; A J Chiausa
Journal:  Science       Date:  1992-10-16       Impact factor: 47.728

9.  MicroRNAs modulate the chemosensitivity of tumor cells.

Authors:  Paul E Blower; Ji-Hyun Chung; Joseph S Verducci; Shili Lin; Jong-Kook Park; Zunyan Dai; Chang-Gong Liu; Thomas D Schmittgen; William C Reinhold; Carlo M Croce; John N Weinstein; Wolfgang Sadee
Journal:  Mol Cancer Ther       Date:  2008-01-09       Impact factor: 6.261

10.  KEGG Atlas mapping for global analysis of metabolic pathways.

Authors:  Shujiro Okuda; Takuji Yamada; Masami Hamajima; Masumi Itoh; Toshiaki Katayama; Peer Bork; Susumu Goto; Minoru Kanehisa
Journal:  Nucleic Acids Res       Date:  2008-05-13       Impact factor: 16.971

View more
  76 in total

Review 1.  Humanized mice for immune checkpoint blockade in human solid tumors.

Authors:  Henry Yip; Carl Haupt; Grace Maresh; Xin Zhang; Li Li
Journal:  Am J Clin Exp Urol       Date:  2019-10-15

2.  Modulation of MicroRNAs by Chemical Carcinogens and Anticancer Drugs in Human Cancer: Potential Inkling to Therapeutic Advantage.

Authors:  Subrata Haldar; Aruna Basu
Journal:  Mol Cell Pharmacol       Date:  2011-01-01

3.  A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.

Authors:  L A Selth; R Das; S L Townley; I Coutinho; A R Hanson; M M Centenera; N Stylianou; K Sweeney; C Soekmadji; L Jovanovic; C C Nelson; A Zoubeidi; L M Butler; G J Goodall; B G Hollier; P A Gregory; W D Tilley
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

Review 4.  Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60.

Authors:  William C Reinhold; Margot Sunshine; Sudhir Varma; James H Doroshow; Yves Pommier
Journal:  Clin Cancer Res       Date:  2015-06-05       Impact factor: 12.531

5.  The NCI-60 Methylome and Its Integration into CellMiner.

Authors:  William C Reinhold; Sudhir Varma; Margot Sunshine; Vinodh Rajapakse; Augustin Luna; Kurt W Kohn; Holly Stevenson; Yonghong Wang; Holger Heyn; Vanesa Nogales; Sebastian Moran; David J Goldstein; James H Doroshow; Paul S Meltzer; Manel Esteller; Yves Pommier
Journal:  Cancer Res       Date:  2016-12-06       Impact factor: 12.701

6.  Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.

Authors:  Eric Polley; Mark Kunkel; David Evans; Thomas Silvers; Rene Delosh; Julie Laudeman; Chad Ogle; Russell Reinhart; Michael Selby; John Connelly; Erik Harris; Nicole Fer; Dmitriy Sonkin; Gurmeet Kaur; Anne Monks; Shakun Malik; Joel Morris; Beverly A Teicher
Journal:  J Natl Cancer Inst       Date:  2016-05-31       Impact factor: 13.506

7.  CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set.

Authors:  William C Reinhold; Margot Sunshine; Hongfang Liu; Sudhir Varma; Kurt W Kohn; Joel Morris; James Doroshow; Yves Pommier
Journal:  Cancer Res       Date:  2012-07-15       Impact factor: 12.701

8.  RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB.

Authors:  William C Reinhold; Sudhir Varma; Margot Sunshine; Fathi Elloumi; Kwabena Ofori-Atta; Sunmin Lee; Jane B Trepel; Paul S Meltzer; James H Doroshow; Yves Pommier
Journal:  Cancer Res       Date:  2019-05-21       Impact factor: 12.701

9.  Epigenetic and genetic inactivation of tyrosyl-DNA-phosphodiesterase 1 (TDP1) in human lung cancer cells from the NCI-60 panel.

Authors:  Rui Gao; Benu Brata Das; Raghunath Chatterjee; Ogan D Abaan; Keli Agama; Renata Matuo; Charles Vinson; Paul S Meltzer; Yves Pommier
Journal:  DNA Repair (Amst)       Date:  2013-12-16

10.  CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics.

Authors:  Augustin Luna; Fathi Elloumi; Sudhir Varma; Yanghsin Wang; Vinodh N Rajapakse; Mirit I Aladjem; Jacques Robert; Chris Sander; Yves Pommier; William C Reinhold
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.